Pharma

Jan 19 2018

Bad science warning: More than 30, 000 studies may have been compromised by contaminated cell lines used for decades –, raptor pharma.#Raptor #pharma

Bad science warning: More than 30,000 studies may have been compromised by contaminated cell lines used for decades Wednesday, October 18, 2017 by: Isabelle Z. (Natural News) What if everything you thought you knew turned out to be wrong? Books and movies have posed this dramatic question in the past, but now it could become reality as new research casts doubt on the cell samples used for more than 30,000 scientific studies. According to a report out of Radboud University in the Netherlands, 451 cell cultures that were used for thousands of scientific experiments are contaminated, and this could have …

Dec 26 2017

Raptor pharma #pharma #crm

#raptor pharma # U.S. drug developer Raptor Pharmaceuticals explores sale: sources By Carl O’Donnell n”>(Reuters) – Raptor Pharmaceutical Corp ( RPTP.O ), a U.S. company that develops drugs to treat orphan diseases, is reaching out to investment banks for a financial adviser to explore a sale of itself, according to people familiar with the matter. The pharmaceutical industry is taking a greater interest in so-called orphan drugs because their strong patent protection helps ensure reliable pricing power for drug makers. At the same time, volatile markets are making it difficult for small life sciences companies with expansive development pipelines such …

Dec 26 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #pharma.com

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Dec 26 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #shire #pharma

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Dec 2 2017

Raptor Pharmaceutical Corp #generic #pharma

#raptor pharma # Traders Salivating For Action In Raptor Pharma: Here Are The Facts Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) is a bio-pharmaceutical company that focuses on the development of treatment for people affected by various diseases, including nephropathic cystinosis in adults and children. The stock was seeing some heavy buying action earlier this week on takeover chatter. Reuters said on April 6 Raptor has consulted with investment bankers and financial advisers to explore a potential sale. On Thursday, Bloomberg reported Retrophin, the company founded by Martin Shkreli, was said to be considering a takeover of Raptor Pharmaceutical. Raptor s …

Dec 2 2017

Raptor Pharma to Stop Development of Liver Drug: Here – s Why: Healthy Living #biotechnology #company

#raptor pharma # Raptor Pharma to Stop Development of Liver Drug: Here s Why Raptor Pharma announced that it will no longer pursue the development of its experimental drug RP103 as treatment for the liver disease Nonalcoholic steatohepatitis in children. (Photo. Bill Brooks | Flickr) Raptor Pharmaceutical Corporation is pulling the plug on an experimental drug as treatment for a liver disease. In a statement released on Monday, Sept.14, the biopharmaceutical company said that the drug called RP103 (cysteamine bitartrate) did not meet the main goals in the Phase 2b CyNCh study. The study, which involved 169 participants between 8 …

Dec 2 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #glide #pharma

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Nov 25 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #pharma #canada

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Nov 15 2017

Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know – The Motley Fool #new #pharmaceuticals

#raptor pharma # Raptor Pharmaceutical Stock Upgraded: 3 Things You Need to Know Apr 7, 2016 at 1:15PM Shares of small-cap orphan drug developer Raptor Pharmaceutical (NASDAQ:RPTP ) surged 24% in Wednesday trading, after Reuters reported that investment bankers have been brought on board to discuss a sale of the company. Raptor has declined to comment on the rumors, however, and with Raptor stock now down 5% in Thursday morning trading, enthusiasm for the development may already be waning. But could it be that today’s 5% retracement is giving investors a chance to take a second bite at the apple …

Nov 15 2017

Here s Why Raptor Pharmaceuticals Corp #biotechnology #industry

#raptor pharma # Here s Why Raptor Pharmaceuticals Corp. Plunged Today Sep 14, 2015 at 11:39AM What. Raptor Pharmaceuticals (NASDAQ:RPTP ). a small-cap biopharma company specializing in the development of treatments for rare diseases, saw its stock plunge by nearly 40% today on heavy volume. This massive downward move was precipitated by the announcement that the company’s experimental drug for nonalcoholic steatohepatitis (NASH) in children, RP103, failed to meet its primary endpoint in a second mid-stage trial. Because RP103 reportedly failed to make any meaningful impact on liver fibrosis, Raptor expects to discontinue the drug’s clinical program for NASH following …